Arq - The Hyper Intelligent Investment Engine By Angel Broking

Thyrocare Technologies Limited IPO Views - 26th Apr 2016

Pharmaceutical | Published on Apr 26th 2016


Thyrocare Technologies is one of the leading diagnostic chains in India with market share of ~3% amongst organised players. The core business of the company is diagnostic testing (~97.1% of sales as on 9MFY2016) while the company through its wholly owned subsidiary also operates imaging centres. A differentiated model enables higher margins: Unlike other organized players, which operate more on a B2C model, Thyrocare is more of a B2B player with ~85% of its revenues coming through the channel (as against 30-40% for its peers). This enables the company to keep its other expenditure lower vis-a-vis its peers, which spend higher on promotional expenses. In terms of services, the company is more focused on the preventive & wellness, and the non-preventive segments, while its peers follow a portfolio model of providing a full range of tests and services, which entail higher manpower costs. The company’s operations are relatively more automated in nature, thereby requiring less manpower intervention, unlike its peers which need to employ qualified manpower like Phds and doctors. As a result, employee costs for Thyrocare account for 10% of sales V/s 20% of sales for its peers. This contributes towards the company enjoying better margins compared to the industry (~41% for Thyrocare’s diagnostic business V/s ~26% for Dr Lal Pathlabs). We believe, over the medium term the company would be able to sustain its margins and also scale up its business, given the opportunities in the industry. This coupled with the low capex requirement for the diagnostic segment makes its diagnostic business a high ROIC business. Outlook and Valuation: The company is valued at a P/E multiple of 42.3-44.9x its FY2016E annualised EPS at the lower and upper end of the issue price band. This compares with a P/E multiple of 61.9x FY2016E EPS for Dr Lal Pathlabs. Although the issue seems to be priced at a discount to Dr Lal Pathlabs, we believe that Thyocare’s consolidated ROIC will come under pressure in the near term as it has entered the molecular imaging space by acquiring Nuclear Healthcare Ltd (NHL). According to the company, this business will take 3-4 years to attain peak profitability while it accounts for almost 40% of its fixed assets of the company (as on 9MFY2016). Thus, though Thyrocare could potentially provide listing gains, the pressure on its ROIC in the near term and the not-so cheap valuation demanded by it will keep the upside in the stock limited. We are Neutral on the issue.

Download Full Report

Trade Securely


Portfolio Tracking & Trading Application View Demo